Wealth & Pension Services Group Inc. acquired a new position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,750 shares of the biopharmaceutical company’s stock, valued at approximately $60,000.
Other institutional investors and hedge funds have also modified their holdings of the company. BNP Paribas Arbitrage SA lifted its holdings in shares of Lexicon Pharmaceuticals by 940.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 8,979 shares in the last quarter. Pegasus Asset Management Inc. acquired a new position in Lexicon Pharmaceuticals in the 4th quarter worth $66,000. Paloma Partners Management Co acquired a new position in Lexicon Pharmaceuticals in the 4th quarter worth $73,000. CWM Advisors LLC lifted its holdings in Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 3,030 shares in the last quarter. Finally, D.A. Davidson & CO. acquired a new position in Lexicon Pharmaceuticals in the 4th quarter worth $87,000. 97.85% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:LXRX traded down $0.22 during trading on Thursday, reaching $5.66. 5,934 shares of the company’s stock traded hands, compared to its average volume of 628,017. Lexicon Pharmaceuticals, Inc. has a 12 month low of $4.25 and a 12 month high of $13.97. The company has a market cap of $607.86 million, a PE ratio of -5.16 and a beta of 0.72.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). Lexicon Pharmaceuticals had a negative net margin of 214.93% and a negative return on equity of 911.37%. The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $13.26 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The company’s revenue for the quarter was down 63.8% compared to the same quarter last year. As a group, analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.47 earnings per share for the current fiscal year.
A number of equities analysts have commented on LXRX shares. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 24th. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Thursday, January 24th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 25th. Wedbush boosted their target price on shares of Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Monday, March 4th. Finally, Gabelli downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 13th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $16.38.
ILLEGAL ACTIVITY WARNING: “Wealth & Pension Services Group Inc. Acquires Shares of 10,750 Lexicon Pharmaceuticals, Inc. (LXRX)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2019/05/23/wealth-pension-services-group-inc-acquires-shares-of-10750-lexicon-pharmaceuticals-inc-lxrx.html.
Lexicon Pharmaceuticals Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Story: Net Income
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.